Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.

Abstract:

BACKGROUND:Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. AIM:To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both drugs following administration on day 1 and day 6. METHODS:Randomized, two-way crossover study. Sixteen Helicobacter pylori-negative healthy subjects, whose gastric acidity fell below pH 4 for 70% of a 24-h baseline period were included. Intragastric pH was measured continuously. RESULTS:On day 1 both drugs significantly raised median 24-h gastric pH compared to baseline. Median pH and percentages of time above pH 3 and 4 on day 1 and day 6 of administration were not significantly different, with the exception of median daytime pH on day 6, which was significantly higher with omeprazole (4.65 vs. 4.05). AUC and Cmax of omeprazole were significantly increased on day 6. AUC and Cmax of pantoprazole were not significantly increased. CONCLUSIONS:No significant difference in acid-inhibitory effect on day 1. On day 6 median daytime pH was significantly higher with omeprazole MUPS, but the percentages of time spent above pH 3 and 4 were not significantly different. The significant increase in bioavailability of omeprazole may contribute to the increased effect on day 6.

journal_name

Aliment Pharmacol Ther

authors

Geus WP,Mathôt RA,Mulder PG,Lamers CB

doi

10.1046/j.1365-2036.2000.00806.x

subject

Has Abstract

pub_date

2000-08-01 00:00:00

pages

1057-64

issue

8

eissn

0269-2813

issn

1365-2036

pii

apt806

journal_volume

14

pub_type

临床试验,杂志文章
  • Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.

    abstract:BACKGROUND:The duration of Helicobacter pylori eradication regimens has decreased to 1 week with cure rates of over 90%. This can be attributed to the use of triple drug regimens including potent inhibitors of gastric acid secretion and clarithromycin. There is no theoretical reason why shorter regimens should not be p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1999.00574.x

    authors: Grimley CE,Penny A,O'sullivan M,Shebani M,Lismore JR,Cross R,Illing RC,Loft DE,Nwokolo CU

    更新日期:1999-07-01 00:00:00

  • NSAIDs: a clinical approach to the problems of gastrointestinal side-effects.

    abstract::Despite the fact that non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs in medicine today, 2-10% of patients must discontinue their use primarily due to gastrointestinal (GI) side-effects. While the development of non-aspirin NSAIDs (NA-NSAIDs) has significantly reduced GI side-effect...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1988.tb00771.x

    authors: Butt JH,Barthel JS,Hosokawa MC,Moore RA

    更新日期:1988-01-01 00:00:00

  • Review article: intestinal failure.

    abstract::Intestinal failure is a specific disease entity resulting from intestinal resection or disease-associated malabsorption and characterized by the inability to maintain protein-energy, fluid, electrolyte or micronutrient balance. We performed a MEDLINE search (1966-2006) to identify relevant articles, using keywords int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02941.x

    authors: Lal S,Teubner A,Shaffer JL

    更新日期:2006-07-01 00:00:00

  • Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.

    abstract::Unfractioned heparin was recently reported to be beneficial in the treatment of inflammatory bowel disease. The available uncontrolled data show that it may be effective in steroid-resistant ulcerative colitis with a percentage of complete clinical remission of over 70% after an average of 4-6 weeks of therapy. The ad...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00860.x

    authors: Papa A,Danese S,Gasbarrini A,Gasbarrini G

    更新日期:2000-11-01 00:00:00

  • Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis.

    abstract:BACKGROUND:Studies on the use of low-dose proton pump inhibitor for the maintenance therapy of gastro-oesophageal reflux disease have shown that it might be comparable with standard-dose proton pump inhibitor treatment and superior to standard-dose histamine-2 receptor antagonist therapy. AIM:To compare the impact of ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01526.x

    authors: You JH,Lee AC,Wong SC,Chan FK

    更新日期:2003-03-15 00:00:00

  • The use of pictograms improves symptom evaluation by patients with functional dyspepsia.

    abstract:BACKGROUND:No validated patient-reported outcome (PRO) measure exists for functional dyspepsia (FD) assessment. Verbal descriptions of different upper abdominal symptoms may be poorly distinguishable to patients. AIM:To investigate whether understanding of FD symptoms is enhanced by pictograms symbolising the nature o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12855

    authors: Tack J,Carbone F,Holvoet L,Vanheel H,Vanuytsel T,Vandenberghe A

    更新日期:2014-09-01 00:00:00

  • Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients.

    abstract:BACKGROUND:There is increasing evidence that impaired mucosal defence mechanisms are implicated in the pathogenesis of the functional gastrointestinal disorders (FGIDs), allowing inappropriate immune activation. AIM:To test the hypothesis that an excess of autoimmune disorders among sufferers, using a large primary ca...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12903

    authors: Ford AC,Talley NJ,Walker MM,Jones MP

    更新日期:2014-10-01 00:00:00

  • Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.

    abstract:BACKGROUND:Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical trials. AIM:To assess the effectiveness and safety of OCA...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16181

    authors: Gomez E,Garcia Buey L,Molina E,Casado M,Conde I,Berenguer M,Jorquera F,Simón MA,Olveira A,Hernández-Guerra M,Mesquita M,Presa J,Costa-Moreira P,Macedo G,Arenas JI,Manuel Sousa J,Ampuero J,Morillas RM,Santos A,De Car

    更新日期:2020-12-12 00:00:00

  • Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.

    abstract:AIM:To appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment. METHODS:Fourteen patients were included in the induction of tolerance protocol. E...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03026.x

    authors: Duburque C,Lelong J,Iacob R,Seddik M,Desreumaux P,Fournier C,Wallaert B,Cortot A,Colombel JF

    更新日期:2006-09-01 00:00:00

  • Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.

    abstract:BACKGROUND:Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies. AIMS:To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FD...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15726

    authors: Dulai PS,Jairath V,Khanna R,Ma C,McCarrier KP,Martin ML,Parker CE,Morris J,Feagan BG,Sandborn WJ

    更新日期:2020-06-01 00:00:00

  • Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.

    abstract:BACKGROUND:The eradication rates following standard triple therapy for Helicobacter pylori infection are declining worldwide. Recent studies have shown that sequential therapy for H. pylori infection yields high cure rates. AIM:To compare the efficacy and tolerability of a sequential regimen as first-line treatment of...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2011.04902.x

    authors: Park HG,Jung MK,Jung JT,Kwon JG,Kim EY,Seo HE,Lee JH,Yang CH,Kim ES,Cho KB,Park KS,Lee SH,Kim KO,Jeon SW

    更新日期:2012-01-01 00:00:00

  • Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.

    abstract:BACKGROUND:There is a lack of evidence for the efficacy of preventive medications for peptic ulcers (PUs) among long-term users of non-steroidal anti-inflammatory drugs (NSAIDs) in Japan. AIM:To estimate the preventive effect by normal dose, not high-dose histamine-H2 receptor antagonists (H2RA) for NSAID-induced ulce...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2005.02477.x

    authors: Miyake K,Ueki N,Suzuki K,Shinji Y,Kusunoki M,Hiratsuka T,Nishigaki H,Tatsuguchi A,Futagami S,Wada K,Tsukui T,Nakajima A,Yoshino S,Sakamoto C

    更新日期:2005-06-01 00:00:00

  • Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.

    abstract:BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12202

    authors: Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

    更新日期:2013-03-01 00:00:00

  • Influence of the timing of administration of 300 mg ranitidine on 24-hour gastric pH in patients acute duodenal ulcer.

    abstract::The 24-hour intragastric pH of 12 patients with an acute duodenal ulcer was recorded with the aim of comparing the effects of two different times of administration of 300 mg ranitidine: post evening meal, or bedtime. This double-blind crossover trial involved 3 centres. Twenty-four-hour gastric pH was measured under s...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1992.tb00562.x

    authors: Cortot A,Guillemot F,Moreau J,Soule JC,Veyrac M,Alberola B,Pappo M

    更新日期:1992-08-01 00:00:00

  • Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

    abstract:BACKGROUND:Vitamin D has immune-regulatory functions in experimental colitis, and low vitamin D levels are present in Crohn's disease. AIM:To assess the effectiveness of vitamin D3 treatment in Crohn's disease with regard to improved disease course. METHODS:We performed a randomized double-blind placebo-controlled tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2010.04355.x

    authors: Jørgensen SP,Agnholt J,Glerup H,Lyhne S,Villadsen GE,Hvas CL,Bartels LE,Kelsen J,Christensen LA,Dahlerup JF

    更新日期:2010-08-01 00:00:00

  • Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study.

    abstract:BACKGROUND:In developed countries, hepatitis E is a porcine zoonosis caused by hepatitis E virus (HEV) genotype 3. In developing countries, hepatitis E is mainly caused by genotype 1, and causes increased mortality in patients with pre-existing chronic liver disease (CLD). AIM:To determine the role of HEV in patients ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13309

    authors: Blasco-Perrin H,Madden RG,Stanley A,Crossan C,Hunter JG,Vine L,Lane K,Devooght-Johnson N,Mclaughlin C,Petrik J,Stableforth B,Hussaini H,Phillips M,Mansuy JM,Forrest E,Izopet J,Blatchford O,Scobie L,Peron JM,Dalton H

    更新日期:2015-09-01 00:00:00

  • Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome.

    abstract:BACKGROUND:Budd-Chiari syndrome (BCS) is a rare but fatal disease caused by obstruction in the hepatic venous outflow tract. AIM:To provide an update of the pathophysiology, aetiology, diagnosis, management and follow-up of BCS. METHODS:Analysis of recent literature by using Medline, PubMed and EMBASE databases. RES...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15149

    authors: Khan F,Armstrong MJ,Mehrzad H,Chen F,Neil D,Brown R,Cain O,Tripathi D

    更新日期:2019-04-01 00:00:00

  • Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.

    abstract:BACKGROUND:Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial. AIM:To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2007.03542.x

    authors: Kajander K,Myllyluoma E,Rajilić-Stojanović M,Kyrönpalo S,Rasmussen M,Järvenpää S,Zoetendal EG,de Vos WM,Vapaatalo H,Korpela R

    更新日期:2008-01-01 00:00:00

  • Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection.

    abstract:BACKGROUND:Hepatitis B (HBV)-infected patients have a higher morbidity and mortality when super-infected by hepatitis A (HAV). AIM:To evaluate the immunogenicity and safety of a commercial inactivated HAV vaccine in Chinese patients with chronic HBV infection. METHODS:Sixty-five HBV-infected patients (30 carriers, 22...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1999.00628.x

    authors: Tsang SW,Sung JJ

    更新日期:1999-11-01 00:00:00

  • Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?

    abstract:BACKGROUND:There are few published data concerning the economic impact of antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in the setting of biliary obstruction. AIM:To perform decision analysis to determine the costs of prophylaxis in patients undergoing endoscopic retrograde cholangiopa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2002.01209.x

    authors: Thompson BF,Arguedas MR,Wilcox CM

    更新日期:2002-04-01 00:00:00

  • The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.

    abstract:BACKGROUND:Uninvestigated dyspepsia is common in family practice. The prevalence of clinically significant upper gastrointestinal findings (CSFs) in adult uninvestigated dyspepsia patients, and their predictability based on history, is unknown. METHODS:Prompt endoscopy was performed within 10 days of referral, in 1040...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01646.x

    authors: Thomson AB,Barkun AN,Armstrong D,Chiba N,White RJ,Daniels S,Escobedo S,Chakraborty B,Sinclair P,Van Zanten SJ

    更新日期:2003-06-15 00:00:00

  • Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study.

    abstract:BACKGROUND:In patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels, liver fibrosis has been reported in 0-22% of cases and advanced liver disease in 5-10% of cases. AIM:To determine whether patients with persistently normal alanine aminotransferase levels clear infe...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2004.01844.x

    authors: Mangia A,Spinzi G,Vuturo O,Pazienza V,Iacobellis A,Piattelli M,Giacobbe A,Leandro G,Piermanni V,Minoli G,Montalto G,Andriulli A

    更新日期:2004-02-01 00:00:00

  • Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.

    abstract:BACKGROUND:Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. AIM:To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). METHODS:A postal questionnaire was sent to all French gastroenterologists among whom 4...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2009.04097.x

    authors: Oussalah A,Roblin X,Laharie D,Filippi J,Flamant M,Faure P,Phelip JM,Bigard MA,Peyrin-Biroulet L

    更新日期:2009-10-15 00:00:00

  • Review article: colorectal carcinoma and inflammatory bowel disease.

    abstract::The risk of colorectal cancer for any patient with ulcerative colitis is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. The relative risk of colorectal cancer in Crohn's colitis is approximately 5.6 and should raise the same concerns as in ulcerative colitis. Risk factors for c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02046.x

    authors: Eaden J

    更新日期:2004-10-01 00:00:00

  • Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.

    abstract:BACKGROUND:The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged. AIM:To inves...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2005.02467.x

    authors: Wada T,Sasaki M,Kataoka H,Tanida S,Itoh K,Ogasawara N,Oshima T,Togawa S,Kubota E,Yamada T,Mori Y,Fujita F,Ohara H,Nakao H,Sobue S,Joh T,Itoh M

    更新日期:2005-06-01 00:00:00

  • Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.

    abstract:BACKGROUND:Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux. Response of laryngitis to treatment with acid-suppressive therapy supports this causal link. AIM:To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and respons...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03185.x

    authors: Qua CS,Wong CH,Gopala K,Goh KL

    更新日期:2007-02-01 00:00:00

  • Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.

    abstract:BACKGROUND:Liver transplantation (LT) offers a possible cure for carefully selected patients with hepatocellular carcinoma (HCC). Studies report that preoperative alpha-fetoprotein (AFP) is a prognostic indicator that can predict survival and recurrence in these patients. AIM:To undertake a systematic review of availa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2012.05060.x

    authors: Hakeem AR,Young RS,Marangoni G,Lodge JP,Prasad KR

    更新日期:2012-05-01 00:00:00

  • A comparison between enprostil and ranitidine in the management of gastric ulceration.

    abstract::In a randomly allocated, double-blind, endoscopically controlled study, 98 patients with gastric ulcers were treated with either (a synthetic prostaglandin of E2-like structure) enprostil 70 micrograms b.d. or 150 mg ranitidine b.d. The healing rates at 4, 8 and 12 weeks were enprostil 57, 91 and 94% and for ranitidin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00511.x

    authors: Morgan AG,Pacsoo C,Taylor P,McAdam WA

    更新日期:1990-12-01 00:00:00

  • Development of a clinical hepatic encephalopathy staging scale.

    abstract:AIM:To develop a scale to assess the severity of hepatic encephalopathy using simple dichotomic items. METHODS:A list of 48 items was created by selecting items that are simple to recognize and categorize; it was applied to thirty-six cirrhotic in-patients with episodic encephalopathy, in addition to the adapted-West-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2007.03394.x

    authors: Ortiz M,Córdoba J,Doval E,Jacas C,Pujadas F,Esteban R,Guardia J

    更新日期:2007-09-15 00:00:00

  • Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.

    abstract:BACKGROUND:Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM:To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS:In this cross-sectional cohort stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13950

    authors: Diederen K,Hoekman DR,Leek A,Wolters VM,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Benninga MA,Kindermann A

    更新日期:2017-04-01 00:00:00